Pharmacy

Naltrexone and acamprosate are the two drugs on the market for patients with alcohol cravings.

The ticket, known as a rare pediatric disease priority review voucher, is part of a program created by Congress in 2007 to encourage the development of drugs for tropical diseases and later expanded to rare pediatric disorders.

Views come as the skyrocketing prices of some drugs are under intense scrutiny, with new evidence showing massive price hikes by some companies.

Gradual price hikes, growth in users pushes up spending for the federal prescription drug program.

The first drug to treat Duchenne muscular dystrophy could sell for $350,000 a year.

HHS says at least 2 million people become infected with antibiotic-resistant bacteria, with 23,000 dying as a result.

Israel-based pharmaceutical company will meet with U.S. FDA to re-submit its marketing application, hopes to launch generic by 2018.

From 2011 to 2015, insurers' payments to hospitals, laboratories, treatment centers and other medical providers for these patients grew from $32 million to $446 million -- a 1,375 percent increase.

Consumers Union wants to know why the cost projections submitted by Anthem and Blue Shield are so much higher than some of their competitors and other industry-wide figures.

While the pharmaceutical industry has historically interacted with patients through clinical trials and marketing efforts, those types of engagement may no longer be enough.